Autopsy report · NCT02394522

Spatial Repellent Products for Control of Vector Borne Diseases - Malaria - Zambia (SR-M-ZM)

“sponsors”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Na

Sponsor

University of Notre Dame

Sponsor type

University, hospital or other

Conditions

Malaria

Interventions

Spatial Repellent product with active ingredient (SHIELD); Active Ingredient; Spatial Repellent product without active ingredient (SHIELD)

Participants

0

Sites

1

Countries

Zambia

Trials that died the same way

• Natural Soybean-derived Femarelle ®for Patients With Non Alcoholic Fatty Liver Disease
  “Sponsors decision” (83% match in meaning)
• Cymbalta for Fibromyalgia Pain - Predictive Value of Small Fiber Changed
  “Sponsor related” (81% match in meaning)
• Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers
  “Sponsor strategy” (79% match in meaning)
• An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease
  “Sponsor resource allocation” (76% match in meaning)
• Post-Marketing Assessment of Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma Patients
  “Sponsor decision” (75% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.